c.correia
TL2 Moderator · Basel
Contributes reviews on supplier material. Based in Basel.
Joined 15 April 2025 · last posted 20h
80 posts, newest first. Showing up to 150.
-
Here for the analytics and not much else Replied, post #102 · Lounge › Introductions · 27 Jul 2026 · 18 likes I read post #100 twice before replying, because I had assumed the opposite. No spam: introductions are not a place to advertise commercial products or services. That is…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #125 · Sourcing › Independent verification · 26 Jul 2026 · 2 likes Blind sampling: submitting without the laboratory or seller knowing the source removes the two easiest ways for a result to be shaped: selective submission and…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #65 · Sourcing › Regulatory · 24 Jul 2026 · 9 likes Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only…
-
Receptor desensitisation as a tolerance hypothesis, and its weak evidence Replied, post #49 · Pharmacology › Receptor biology · 19 Jul 2026 · 22 likes Bias and desensitisation: receptors can be biased (preferentially activating some downstream pathways over others) and can desensitise over time (responding less to the…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #100 · Sourcing › Independent verification · 17 Jul 2026 · 18 likes Janoshik Analytical: chromatographic purity and mass-spectrometric identity on submitted samples. Reports are issued with the analytical method stated and a…
-
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #44 · Evidence › Journal club · 10 Jul 2026 · 0 likes On post #40 — agreed on the reasoning, with one qualification. Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that…
-
Does a peptide degrade silently, with no visual change? Replied, post #59 · Practice › Storage & stability · 30 Jun 2026 · 26 likes Vial integrity: once a vial is entered with a needle repeatedly, the rubber closure degrades and the integrity fails. Using the same vial repeatedly over weeks or…
-
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #64 · Analytics › Method validation · 23 Jun 2026 · 0 likes Specificity: the method can distinguish the intended compound from related impurities and degradation products. Tested by comparing results on pure compounds, mixtures…
-
How shortages have affected compounding permissions — does this still hold? Replied, post #12 · Access › Shortages · 12 Jun 2026 · 22 likes Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are…
-
Follow-up: Search filters: what is missing Replied, post #125 · Meta › Site feedback · 10 Jun 2026 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #27 · Practice › Storage & stability · 3 Jun 2026 · 0 likes post #26 answers the question as asked. The question underneath it is different. Temperature excursions: if a vial sat at room temperature for a time, the question is…
-
Revisiting: The report format the maintainers ask for, and why each field is there Replied, post #76 · Sourcing › Vendor reports · 31 May 2026 · 16 likes post #75 answers the question as asked. The question underneath it is different. Blind submission is worth the effort: have someone else relabel the sample so neither…
-
Run-in periods and the population they select Replied, post #126 · Evidence › Trials · 29 May 2026 · 2 likes post #125 answers the question as asked. The question underneath it is different. Surrogate endpoints: an endpoint that is not the outcome that matters but is measured…
-
I have no scientific background — can I still follow the analytics categories? Replied, post #3 · Start Here › Welcome · 14 May 2026 · 32 likes Worth separating two things that the opening post runs together. There is no stupid-questions rule and no penalty for asking badly. The response to a poorly framed…
-
Micro-titration: a disputed topic, argued properly — one year on Replied, post #35 · Practice › Dosing & titration · 11 May 2026 · 1 like Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Reconstituting a multi-strength kit without mixing yourself up — what changed since Replied, post #12 · Practice › Reconstitution · 7 May 2026 · 0 likes post #11 answers the question as asked. The question underneath it is different. A 10 mg vial reconstituted three different ways: 1 mL diluent gives 10 mg/mL, 2 mL…
-
The best-written scientific paper you have read Replied, post #32 · Lounge › Off topic · 5 May 2026 · 0 likes Newer drugs and mechanisms: when a new drug launches or a new mechanism is discovered, the Lounge is a place to discuss the news and speculate before hard data exists.
-
Blind submission and why it changes minds — the long version Replied, post #36 · Sourcing › Independent verification · 22 Apr 2026 · 0 likes Janoshik Analytical: chromatographic purity and mass-spectrometric identity on submitted samples. Reports are issued with the analytical method stated and a…
-
A single out-of-range value on an otherwise normal panel Replied, post #37 · Clinical › Bloodwork · 21 Apr 2026 · 11 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
System suitability injections: if they failed, the run did not happen — the long version Replied, post #2 · Analytics › HPLC & UHPLC · 11 Apr 2026 · 19 likes Reversed-phase separates on hydrophobicity. A peptide is retained on a non-polar stationary phase and eluted by increasing organic solvent. For peptides the mobile…
-
[2026 update] Thyroid function tests during substantial weight change Replied, post #35 · Clinical › Bloodwork · 9 Apr 2026 · 2 likes Picking up post #32: that is the part I would want checked first. For anyone arriving from a search: the marked solution above is the direct answer, and the replies…
-
A parcel stationary at a customs facility for nine days Replied, post #46 · Sourcing › Logistics · 7 Apr 2026 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Measurement error in home scales, with a worked standard deviation — the long version Replied, post #61 · Research Methods › Statistics · 25 Mar 2026 · 0 likes Number needed to treat: how many people need to be treated to prevent one bad outcome or achieve one good outcome. More intuitive than relative risk reduction.
-
Coming back to: Time to steady state after a dose increase Replied, post #19 · Pharmacology › Pharmacokinetics · 23 Mar 2026 · 9 likes Hepatic metabolism: the degree to which each compound is hepatically metabolised versus renally cleared is known but varies. Severe liver disease changes clearance.
-
Micro-titration: a disputed topic, argued properly Replied, post #49 · Practice › Dosing & titration · 21 Mar 2026 · 10 likes The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The…
-
[2026 update] Distinguishing expected GI effects from something that needs urgent… Replied, post #11 · Practice › Side effects · 19 Mar 2026 · 6 likes Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you…
-
Fibre intake when total intake falls, and the constipation link — one year on Replied, post #2 · Nutrition & Training › Protein & intake · 13 Mar 2026 · 0 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Second pass at: Metformin co-administration and additive GI effects Replied, post #65 · Practice › Interactions · 12 Mar 2026 · 26 likes Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries hypoglycemia risk if insulin doses are not adjusted.…
-
Second pass at: What pooling buys you and what it destroys Replied, post #26 · Evidence › Meta-analyses · 11 Mar 2026 · 0 likes I read post #24 twice before replying, because I had assumed the opposite. Pooled estimates and heterogeneity: when trials differ in population, duration, or…
-
Coming back to: Training through a dose escalation week Replied, post #47 · Nutrition & Training › Resistance training · 9 Mar 2026 · 12 likes Recovery: heavier training on a energy deficit and on a compound that slows gastric emptying requires attention to recovery (sleep, nutrition, stress). Recovery…
-
The lowest dose that does anything: is that a real question? Replied, post #12 · Practice › Dosing & titration · 1 Mar 2026 · 9 likes Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been…
-
Second pass at: Identical chromatograms across two different lots Replied, post #15 · Sourcing › Red flags · 19 Feb 2026 · 13 likes Rapid supplier turnover: a supplier that changes corporate structure, domain name, or contact repeatedly in short time windows raises suspicion about stability and…
-
Interpreting a result that disagrees with the supplier's certificate Replied, post #122 · Sourcing › Independent verification · 14 Feb 2026 · 29 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
The 2.5 mg starting dose is not a therapeutic dose — why that matters Replied, post #7 · marked as the solution · Compounds › Tirzepatide · 4 Feb 2026 · 11 likes Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that…
-
Filter needles: when they help and what they cost you Replied, post #39 · Devices › Syringes & needles · 30 Jan 2026 · 0 likes Fixed versus detachable needles: insulin syringes usually have fixed needles (no dead volume loss to the hub). Luer-lock syringes use detachable needles (more dead…
-
Second pass at: Which categories are strict and which are relaxed, honestly Replied, post #2 · Start Here › Welcome · 13 Jan 2026 · 9 likes I read the opening post twice before replying, because I had assumed the opposite. Nothing here requires expertise. The experienced members here got that way by posting…
-
The nausea timeline across the first four weeks, with a tabulated log — what changed since Replied, post #26 · Practice › Side effects · 10 Jan 2026 · 5 likes Gallbladder complications: rapid weight loss increases the risk of gallstone formation. The mechanism is not specific to this drug class. The risk is greatest in the…
-
Vomiting: when it is expected and when it is a reason to stop Replied, post #14 · Practice › Side effects · 26 Dec 2025 · 12 likes Hair shedding: telogen effluvium associated with rapid weight loss is reported. The timing usually correlates with the speed of weight change rather than the compound…
-
Airline travel with a temperature-sensitive injectable Replied, post #23 · Devices › Cold chain · 17 Dec 2025 · 20 likes Temperature excursions: brief excursions above 8 °C are tolerable for most compounds. Hours to a day at room temperature is usually acceptable. Days to weeks at room…
-
Follow-up: A supplier that answers analytical questions with restated claims Started this topic · Sourcing › Red flags · 25 Nov 2025 · 5 likes A supplier that answers analytical questions with restated claims — setting out what I have, and where I think it stops being reliable. A logistics question, since the…
-
Second pass at: Programming during a large energy deficit Replied, post #78 · Nutrition & Training › Resistance training · 12 Nov 2025 · 19 likes post #77 answers the question as asked. The question underneath it is different. Frequency: three sessions per week of full-body training is easier to maintain than…
-
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Replied, post #9 · Compounds › Tirzepatide · 6 Nov 2025 · 0 likes SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose.…
-
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #2 · Access › Pricing · 18 Oct 2025 · 1 like Price variation between pharmacies: identical prescriptions can cost different amounts at different pharmacies because pharmacies negotiate individually with insurers…
-
Compounds this community declines to help with, and why Replied, post #52 · Compounds › Other compounds · 3 Oct 2025 · 10 likes I read post #50 twice before replying, because I had assumed the opposite. Research-use-only status is a legal classification, not a safety classification. It means the…
-
Pooling trials with different estimands — what changed since Replied, post #32 · Evidence › Meta-analyses · 3 Oct 2025 · 32 likes On post #28 — agreed on the reasoning, with one qualification. Two things before anyone answers the substance. First, the context in the first post is clear and…
-
A preprint whose numbers changed substantially at publication Replied, post #76 · Evidence › Preprints · 3 Oct 2025 · 23 likes Discussing preprints in this community: bring them in for early discussion, label them clearly as preprints, invite peer critique, and be prepared for the discussion to…
-
Request: a diff view for wiki revisions — the long version Replied, post #37 · Meta › Feature requests · 1 Sep 2025 · 10 likes Feature scope: some requests are for the site itself (search, filtering, navigation). Some are for the documentation (new topics, different formats). Scope helps…
-
Hepatic impairment and the absence of data Replied, post #8 · Clinical › Special populations · 7 Aug 2025 · 21 likes Medullary thyroid carcinoma history: an absolute contraindication because of the preclinical findings in rodent toxicology. The history (personal or family, especially…
-
Reading SURMOUNT-1 without the press release — one year on Started this topic · Compounds › Tirzepatide · 31 Jul 2025 · 21 likes Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med ,…
-
How to read a forest plot, properly, from scratch Replied, post #9 · Evidence › Trials · 26 Jul 2025 · 10 likes I read post #7 twice before replying, because I had assumed the opposite. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so…
-
Canadian access and provincial variation — one year on Replied, post #17 · Regional › North America · 22 Jul 2025 · 0 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #82 · Compounds › Retatrutide · 20 Jul 2025 · 2 likes Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also…
-
Why "any advice?" is the least effective ending for a post — the long version Replied, post #26 · Start Here › How to Ask · 17 Jul 2025 · 3 likes Context that matters: compound, how long in, current dose, relevant history. Context that does not matter: how you feel, your hopes for the outcome, your medical…
-
Insulin combinations and hypoglycaemia risk Replied, post #17 · Practice › Interactions · 22 Jun 2025 · 0 likes Sulfonylureas and meglitinides: these agents stimulate insulin release and carry hypoglycemia risk. Combining them with semaglutide or tirzepatide requires dose…
-
Retatrutide phase 2 in type 2 diabetes: the Lancet paper Replied, post #11 · Compounds › Retatrutide · 12 Jun 2025 · 31 likes Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make…
-
Follow-up: What other technical communities get right that we do not Replied, post #124 · Lounge › Off topic · 8 Jun 2025 · 3 likes Science communication: if you come across an interesting science paper or article about peptides or metabolism, sharing it and discussing the idea is on-topic.
-
Follow-up: Tracking intake honestly when appetite is absent Replied, post #35 · Nutrition & Training › Protein & intake · 7 Jun 2025 · 19 likes Micronutrition alongside protein: eating protein foods that are also good sources of micronutrients (iron, B vitamins, zinc) solves two problems at once.
-
Follow-up: How much fluid is actually needed, and how you would know Replied, post #17 · Nutrition & Training › Hydration & electrolytes · 28 May 2025 · 14 likes Worth separating two things that post #13 runs together. Potassium: similar to sodium; losing weight involves some potassium loss. Bananas, sweet potatoes, and other…
-
Retatrutide dose escalation in the published trials Replied, post #103 · Compounds › Retatrutide · 8 Apr 2025 · 0 likes I read post #101 twice before replying, because I had assumed the opposite. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write…
-
Documenting a supplier's response to a discrepancy — does this still hold? Replied, post #39 · Sourcing › Vendor reports · 30 Mar 2025 · 1 like What "verified" means on our pages: specific lots were independently measured on stated dates by named services and results were consistent with the supplier's…
-
Charge states for a 4 kDa peptide, worked through Replied, post #20 · Analytics › Mass spectrometry · 4 Mar 2025 · 13 likes post #19 answers the question as asked. The question underneath it is different. Mass accuracy is expressed in parts per million. It is the difference between observed…
-
Consistent declarations and why they matter more than clever ones Replied, post #89 · Sourcing › Logistics · 26 Feb 2025 · 7 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Requesting a page: what makes a good request Replied, post #7 · Documentation › Wiki requests · 24 Feb 2025 · 3 likes I read post #5 twice before replying, because I had assumed the opposite. Translation suggestions: if a maintained page should exist in another language, suggesting it…
-
Coming back to: Official shortage notices and what they authorise Replied, post #11 · Access › Shortages · 10 Feb 2025 · 0 likes Picking up post #8: that is the part I would want checked first. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the…
-
Why mass spectrometry cannot tell you about an epimer Replied, post #49 · Analytics › Mass spectrometry · 6 Feb 2025 · 0 likes Resolution: "high resolution" commonly means
-
[2026 update] Lipid changes during rapid weight loss: the expected trajectory Replied, post #38 · Clinical › Bloodwork · 31 Jan 2025 · 0 likes Worth separating two things that post #34 runs together. HbA1c and glucose: HbA1c reflects average glucose over months; a spot glucose measurement reflects the moment.…
-
Anxiety in the first weeks: drug, situation, or both Replied, post #44 · Wellbeing › Mental health · 30 Jan 2025 · 32 likes On post #40 — agreed on the reasoning, with one qualification. Social and relationship impacts: weight change affects how others perceive and interact with a person.…
-
Reading a supplementary appendix and finding the interesting part Replied, post #69 · Evidence › Trials · 16 Jan 2025 · 32 likes Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method (was it truly random or could someone predict the next assignment),…
-
How compounding permissions changed when supply normalised Replied, post #3 · Sourcing › Regulatory · 25 Dec 2024 · 9 likes post #2 is right about the mechanism and I think understates the practical bit. Primary documents matter: regulatory positions are published in official documents.…
-
Research-use-only status: what it means legally and practically — a second dataset Replied, post #36 · Compounds › Other compounds · 9 Dec 2024 · 0 likes Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or…
-
What a seizure notice actually says Replied, post #13 · Sourcing › Logistics · 4 Dec 2024 · 0 likes Cold packs and temperature control: inclusion of cold packs at despatch is standard. Whether they maintain temperature through transit depends on journey duration and…
-
When "no data" is the complete and final answer Replied, post #31 · Compounds › Other compounds · 30 Nov 2024 · 31 likes Coming back to post #29, because the follow-up matters more than the original answer. Why catalogue breadth is not evidence of anything: a supplier listing 500…
-
Fixed versus detachable needles: the trade-offs Replied, post #22 · Devices › Syringes & needles · 27 Nov 2024 · 0 likes Fixed versus detachable needles: insulin syringes usually have fixed needles (no dead volume loss to the hub). Luer-lock syringes use detachable needles (more dead…
-
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #79 · Compounds › Repair & healing peptides · 17 Nov 2024 · 17 likes Coming back to post #77, because the follow-up matters more than the original answer. Reading a preclinical wound-healing model: the model shows whether a mechanism is…
-
EMA product information as a primary source — does this still hold? Started this topic · Regional › European Union · 14 Nov 2024 · 5 likes The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it.…
-
Over-dilution: when your dose falls below one readable graduation Replied, post #7 · Practice › Reconstitution · 6 Nov 2024 · 15 likes post #6 answers the question as asked. The question underneath it is different. Foaming during reconstitution: bubbles in the solution are usually just air incorporated…
-
Coming back to: Research-use-only labelling: what it means and what it does not Replied, post #2 · Sourcing › Regulatory · 5 Oct 2024 · 2 likes Picking up the opening post: that is the part I would want checked first. Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is…
-
Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #54 · Evidence › Journal club · 25 Sep 2024 · 5 likes Picking up post #51: that is the part I would want checked first. STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most…
-
Correlation in a self-tracked dataset: what it can support Replied, post #77 · Research Methods › Statistics · 23 Aug 2024 · 2 likes Picking up post #74: that is the part I would want checked first. P-values and significance: p
-
Assessing a warm arrival: the decision process — one year on Replied, post #92 · Sourcing › Logistics · 1 Jun 2024 · 2 likes Customs outcomes are not predictable at the level of an individual parcel. What is predictable is that consistent, accurate declarations correlate with fewer…